Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
From
elpais
Un tratamiento experimental logra revertir el sistema inmunológico y curar a pacientes con enfermedad de Crohn 
No comment yet.
Sign up to comment
|
Scoop.it!
Largest Microbiome Study on Newly Diagnosed Patients Gives Insight Into Crohn's Disease and Shows Antibiotic Treatment May Worsen Disease
Alfredo Corell's insight:
Summary
Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent among published studies. Using samples from multiple gastrointestinal locations collected prior to treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status. Microbiome comparison between CD patients with and without antibiotic exposure indicates that antibiotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial signatures between the ileum, the rectum, and fecal samples indicates that at this early stage of disease, assessing the rectal mucosal-associated microbiome offers unique potential for convenient and early diagnosis of CD. Divulgative news: http://www.sys-con.com/node/3009818
|
Azucena Salas incide en el equilibrio entre esperanzas y riesgos: “Ver con tus propios ojos casos de recuperación completa como el de Javier es ilusionante. Los datos confirman que podemos resetear el sistema inmunológico de pacientes con enfermedades autoinmunes, lo cual es muy esperanzador. Pero advertirles de que hay riesgo de muerte es muy duro, y sólo merece la pena en casos muy concretos en que sepamos que la terapia va a funcionar. Debemos seguir investigando”.